東方生物(688298.SH):已於2024年度完成在美國本土化生產基地佈局
格隆匯4月23日丨東方生物(688298.SH)在互動平台表示,美國市場是公司重點戰略佈局市場之一,目前約1/3左右產品出口到美國,關税問題會帶來一定程度的影響。但是,公司非常重視中美關税政策,積極採取應對措施,公司已於2024年度完成在美國本土化生產基地佈局,配備了數十條自動化生產線,具備本土化量產能力;同時,在市場佈局上,公司將重點加大國內市場的拓展力度,現已取得一定的成效和產品市場積澱,另外,將繼續發揮歐洲核心市場地位,同時延展亞洲、一帶一路等區域市場的佈局;最後,公司將通過降本增效、客户協商定價等措施,盡力降低關税帶來的綜合影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.